{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:14:09Z","timestamp":1783480449538,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hpb.2026.04.448","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:33Z","timestamp":1776408633000},"page":"918-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6893-8084","authenticated-orcid":false,"given":"Xiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1576-1032","authenticated-orcid":false,"given":"Shruthi R.","family":"Perati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7304-0124","authenticated-orcid":false,"given":"Sana M.","family":"Mohayya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Shippey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0745-3341","authenticated-orcid":false,"given":"Henry A.","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam F.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2026.04.448_bib1","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-20-1088","article-title":"Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study","volume":"30","author":"Flores","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.hpb.2026.04.448_bib2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.hpb.2021.12.022","article-title":"A nationwide analysis of clinical trial participation for common hepato-pancreato-biliary malignancies demonstrates survival advantages for subsets of trial patients but disparities in and infrequency of enrollment","volume":"24","author":"Elshami","year":"2022","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.hpb.2026.04.448_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hpb.2026.04.448_bib4","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1245\/s10434-023-14288-4","article-title":"The impact and opportunity of inclusive excellence: addressing social determinants of health in cancer clinical trials","volume":"30","author":"Vickers","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2026.04.448_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.amepre.2015.08.024","article-title":"County health rankings: relationships between determinant factors and health outcomes","volume":"50","author":"Hood","year":"2016","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.hpb.2026.04.448_bib6","series-title":"Vizient vulnerability index public access","year":"2025"},{"key":"10.1016\/j.hpb.2026.04.448_bib7","first-page":"166","article-title":"Current status of liver allocation in the United States","volume":"12","author":"Elwir","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2026.04.448_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11901-020-00554-6","article-title":"Racial and sex disparities in hepatocellular carcinoma in the USA","volume":"19","author":"Ajayi","year":"2020","journal-title":"Curr Hepat Rep"},{"key":"10.1016\/j.hpb.2026.04.448_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.16367","article-title":"Projected trends in metabolic dysfunction-associated steatotic liver disease mortality through 2040","volume":"8","author":"Zhang","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpb.2026.04.448_bib10","article-title":"Social determinants of health associated with metabolic dysfunction-associated steatotic liver disease prevalence and severity: a systematic review and meta-analysis","volume":"17","author":"Abu-Rumaileh","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.hpb.2026.04.448_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00375","article-title":"Increased risk of hepatocellular carcinoma associated with neighborhood concentrated disadvantage","volume":"8","author":"Danos","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.hpb.2026.04.448_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.22515","article-title":"Racial and ethnic inequities in US oncology clinical trial participation from 2017 to 2022","volume":"6","author":"Pittell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpb.2026.04.448_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/XCS.0000000000000129","article-title":"Disparity in clinical trial participation among patients with gastrointestinal cancer","volume":"234","author":"Abbas","year":"2022","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.hpb.2026.04.448_bib14","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1245\/s10434-007-9500-y","article-title":"Participation in surgical oncology clinical trials: gender-, race\/ethnicity-, and age-based disparities","volume":"14","author":"Stewart","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2026.04.448_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cncr.33991","article-title":"Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials","volume":"128","author":"Javier-DesLoges","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2026.04.448_bib16","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1161\/STROKEAHA.120.028530","article-title":"Impact of multiple social determinants of health on incident stroke","volume":"51","author":"Reshetnyak","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.hpb.2026.04.448_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.120.048026","article-title":"Number of social determinants of health and fatal and nonfatal incident coronary heart disease in the REGARDS Study","volume":"143","author":"Safford","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.hpb.2026.04.448_bib18","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncr.33894","article-title":"Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study","volume":"128","author":"Pinheiro","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2026.04.448_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/OP.24.00261","article-title":"State of geographic access to cancer treatment trials in the United States: are studies located where patients live?","volume":"21","author":"Kirkwood","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.hpb.2026.04.448_bib20","article-title":"Clinical trial deserts for gastrointestinal cancer in the United States: association with area deprivation and digital divide","volume":"6","author":"Chatzipanagiotou","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2026.04.448_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/OP.24.00206","article-title":"Association of community-level social vulnerability with clinical trial discussion and participation among cancer survivors","volume":"21","author":"Sekar","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.hpb.2026.04.448_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s13187-024-02440-x","article-title":"Impact of clinical trial design on recruitment of racial and ethnic minorities","volume":"39","author":"Sheikh","year":"2024","journal-title":"J Cancer Educ"},{"key":"10.1016\/j.hpb.2026.04.448_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.20053","article-title":"Association of remote technology use and other decentralization tools with patient likelihood to enroll in cancer clinical trials","volume":"5","author":"Adams","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpb.2026.04.448_bib24","first-page":"565","article-title":"Patient navigation across the cancer care continuum: an overview of systematic reviews and emerging literature","volume":"73","author":"Chan","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.hpb.2026.04.448_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1353\/cpr.2012.0038","article-title":"Assessing an intervention to improve clinical trial perceptions among predominately African-American communities in South Carolina","volume":"6","author":"Ford","year":"2012","journal-title":"Prog Community Health Partnership"},{"key":"10.1016\/j.hpb.2026.04.448_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2012-0454","article-title":"A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials","volume":"17","author":"Banda","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.hpb.2026.04.448_bib27","article-title":"Addressing financial barriers to patient participation in clinical trials: ASCO Policy statement","volume":"13","author":"Winkfield","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2026.04.448_bib28","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cncr.33905","article-title":"Strategies to improve diversity, equity, and inclusion in clinical trials","volume":"128","author":"Kahn","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.hpb.2026.04.448_bib29","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jss.2024.07.116","article-title":"Changes in incidence of cirrhotic and noncirrhotic hepatocellular carcinoma in the United States","volume":"302","author":"Donica","year":"2024","journal-title":"J Surg Res"},{"issue":"5 Suppl 1","key":"10.1016\/j.hpb.2026.04.448_bib30","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hpb.2026.04.448_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2023.7314","article-title":"Analysis and optimization of equitable US cancer clinical trial Center access by travel time","volume":"10","author":"Lee","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26005721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X26005721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:21:45Z","timestamp":1783477305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X26005721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1365182X26005721"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2026.04.448","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials for hepatocellular carcinoma: are we reaching the most vulnerable patients?","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2026.04.448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}